Find Clinical Trials

Back My cancer has not gone away or has come back Cancer progressed on treatment

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target

Return only trials with results

Include all Phase 1 trials (i.e., dose-finding as well as expansion)

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

III

Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab; at most 24 months since last dose of prior platinum therapy - intraperitoneal infusion

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

AL, AZ, CA, FL, IN, MD, MI, MO, NV, NY, NC, OH, OK, PA, SC, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Olvimulogene nanivacirepvec	light-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1	Induces immune response and tumor cell lysis	Clinical Trials

III

Recurrent low grade serous ovarian cancer

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

AZ, AR, CA, CT, FL, GA, IL, LA, MD, MI, MN, MO, NY, NC, OH, OK, OR, PA, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Avutometinib	CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766	RAF and MEK inhibitor	Clinical Trials
Defactinib	VS-6063, PF-04554878, PF-04554878	FAK inhibitor	Clinical Trials

II/III

Platinum resistant FOLR+ high grade serous ovarian cancer with prior bevacizumab (Phase III)

REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)

AZ, CA, DC, FL, MD, MA, MN, NE, NM, NY, OH, OK, OR, PA, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Luveltamab tazevibulin	STRO-002, anti-folate receptor-alpha antibody drug conjugate STRO-002	ADC: anti-FRalpha + microtubule destabilizer (SC209)	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

II

Ovarian expansion for FGFR2 fusion, rearrangement or mutation or Advanced solid tumors with molecular alterations in CDKN2A, CDKN2B, CHEK2, ERBB2, ERBB3, FGFR3, FLT3, KIT, NTRK1/2/3, PALB2, PDGFRA, PDGFRB, POLE, RAF-1, RET, ROS-1, TSC1/2, VEGFR2, VEGFR3, VHL or HER2+

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

AL, AZ, CA, CT, FL, GA, IL, IN, ME, MI, NE, NH, NM, NY, NC, ND, OH, OR, PA, SC, SD, TN, TX, UT, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Futibatinib	TAS-120, FGFR inhibitor TAS-120	FGFR1-4 inhibitor	Approved in Other Cancers
Larotrectinib	Trk inhibitor LOXO-101, LOXO-101, Vitrakvi	pan-Trk kinase inhibitor	Approved in Other Cancers
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pertuzumab	Perjeta, monoclonal antibody 2C4, rhuMAb2C4	HER2 dimerization inhibitor	Approved in Other Cancers
PHESGO	pertuzumab, trastuzumab, and hyaluronidase-zzxf	HER2 antagonist	Approved in Other Cancers
Regorafanib	BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga	Multi-targeted RTK inhibitor	Approved in Other Cancers
Sunitinib	Sutent, Sunitinib malate	VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit	Approved in Other Cancers
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers
Temsirolimus	Torisel, CCI-779	mTOR inhibitor	Approved in Other Cancers
Trastuzumab	Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody	HER2 antagonist	Approved in Other Cancers
Tucatinib	Irbinitinib, ONT-380	HER2 kinase inhibitor	Approved in Other Cancers

II

Advanced solid tumors with high MSI or high TMB

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

NJ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with HER2 amplification

A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers

II

Advanced solid tumors with CCND1/2/3 alterations or CDK4/6 amplifications

A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers

II

Advanced solid tumors

A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
Individual Patient TCR-Transduced PBL	autologous PBLs retrovirally-transduced with TCRs targeting neoantigens	Immune response against neoantigens	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with ARID1A or ATM alterations

Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	ATR kinase inhibitor AZD6738, AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Selected Young TIL		Immune response against tumor associated antigens	Clinical Trials

II

Advanced solid tumors (with tumor amenable to skin biopsy)

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Capecitabine	CAPE, Xeloda	RNA processing and thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor	NCCN Guidelines for Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors

A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Autologous TILs		Immune response against tumor associated antigens	Clinical Trials
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers

II

Advanced solid tumors that must have progressed on prior immunotherapy or cellular therapy (amenable to radiation therapy)

Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Radiation Therapy	Irradiation, Radiotherapy

II

Advanced solid tumors with brain metastases and NTRK, ROS1, KRAS G12C, CDK pathway or PI3K pathway alterations

Genomically-Guided Treatment Trial in Brain Metastases

AK, AZ, AR, CA, CO, FL, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NJ, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Adagrasib	MRTX849, KRAS G12C inhibitor MRTX849	KRAS G12C inhibitor	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Paxalisib	GDC-0084, PI3K inhibitor GDC-0084, RG7666	PI3K/mTOR inhibitor	Clinical Trials

II

Platinum resistant or refractory ovarian cancer (at most 4 prior therapies for platinum resistant disease)

Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

MI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ONC201	AKT/ERK inhibitor ONC201, TIC10	AKT and ERK kinase inhibitor	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Recurrent ovarian cancer (only detectable by rising CA125)

A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Carboplatin to Prevent Progression After Serologic Detection of Recurrent Ovarian Cancer

WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent granulosa cell ovarian cancer or clear cell ovarian cancer

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nilotinib	AMN 107, Tasigna	Bcr-abl, c-Kit, and PDGFR kinase inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Recurrent ovarian cancer with CCND1-3 or CDK4/6 amplifications or CDKN2A alterations

An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Anastrozole	Arimidex	Aromatase inhibitor
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer

II

Advanced HER2+ (IHC1+, IHC2+ or IHC3+) solid tumors

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

CA, IL, IN, MA, NJ, NY, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Trastuzumab deruxtecan	T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a	ADC: anti-HER2 + topoisomerase I inhibitor (Dxd)	Approved in Ovarian Cancer

II

Advanced solid tumors with alterations in ALK, ATM, KRAS G12C, NTRK1/2/3, ROS1 or SETD2

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

CA, CO, ID, MD, MI, MN, MT, NE, NJ, NY, OH, PA, TN, TX, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Alectinib	AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802	ALK kinase inhibitor	Approved in Other Cancers
Camonsertib	RP-3500	ATR kinase inhibitor	Clinical Trials
Divarasib	GDC-6036	KRAS G12C inhibitor	Clinical Trials
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers

II

Advanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I)

Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Avapritinib		PDGFRa and c-Kit inhibitor	Approved in Other Cancers

II

Patients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A

Phase II Trial of Palbociclib and Pembrolizumab in Central Nervous System Metastases

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers

II

Recurrent Germ Cell Tumors

A Phase II Trial Evaluating the Efficacy of Cabozantinib in the Treatment of Incurable Patients With Refractory Germ Cell Tumors

IN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cabozantinib	BMS-907351, Cabometyx, XL184, Cometriq	Multi-targeted RTK inhibitor	Approved in Other Cancers

II

Advanced solid tumors with NTRK1-3 amplifications (at least 7 copies)

A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Larotrectinib	Trk inhibitor LOXO-101, LOXO-101, Vitrakvi	pan-Trk kinase inhibitor	Approved in Other Cancers

II

Platinum resistant high grade serous ovarian cancer (at most 1 prior therapy for platinum resistant disease)

An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

IL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Mecbotamab Vedotin	CAB-AXL-ADC, BA3011, conditionally active biologic anti-AXL antibody-drug conjugate BA3011	ADC: anti-Axl + microtubule destabilizer (MMAE)	Clinical Trials
Ozuriftamab Vedotin	BA3021	ADC: anti-ROR2 + microtubule destabilizer (MMAE)	Clinical Trials

II

Recurrent ovarian cancer with symptomatic ascites or pleural effusion

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Pegcetacoplan	C3-targeted complement inhibitor APL-2, APL-2	Blocks the cleavage of C3	Approved in Other Indications
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with ARID1A mutations

A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with somatic mutations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCI/L, PALB2, PPP2R2A, RAD51B/C/D or RAD54L

A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer

TN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Dostarlimab	TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with ARID1A mutations

A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

SC

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Tazemetostat	histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438, Tazverik	EZH2 histone methyltransferase inhibitor	Approved in Other Cancers

II

Platinum resistant high grade serous or recurrent clear cell ovarian cancer (at most 2 prior chemotherapy regimens)

A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer

AZ, CA, CO, DE, GA, NY, PA, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Vudalimab	XmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717	Blocks PD-1 and CTLA-4 inhibition of T cells	Clinical Trials

II

Advanced solid tumors with brain metastases

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent ovarian cancer with prior PARP inhibitor (at most 4 prior chemotherapy regimens)

Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers
ZEN-3694	ZEN003694, BET bromodomain inhibitor ZEN-3694	BET inhibitor	Clinical Trials

II

Recurrent low grade serous ovarian cancer

Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial

OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Fulvestrant	ZD9238, ICI 182,780, Faslodex	ER antagonist (SERD)	Approved in Other Cancers
Regorafanib	BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga	Multi-targeted RTK inhibitor	Approved in Other Cancers

II

Ovarian cancer with brain metastases and alterations in ATM, ATR, BAP1, BARD1, BRCA1/2, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, RAD54B/L, XRCC2, or XRCC3 (with measurable disease in the CNS)

Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

II

Recurrent serous, endometrioid or clear cell ovarian cancer

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer

NY, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
CDX-1140		Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum resistant ovarian cancer

A Phase II Trial of Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

IL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Minoxidil		Kir6/SUR2 channel activator	Approved in Other Indications

II

Advanced solid tumors with loss of SMARCB1 or SMARCA1

A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

AL, CA, CO, DC, GA, IL, IN, MD, MA, MI, MN, MO, NY, NC, OH, OR, PA, TN, TX, UT, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tiragolumab	MTIG7192A, RO7092284	Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cells	Clinical Trials

II

Recurrent or persistent clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell component

A Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary

IL, MA, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with alterations in BARD1, BRCA 1/2, BRIP1, FANCA, PALB2; RAD51 or RAD51C/D with prior PARP inhibitor therapy or advanced solid tumors with a KRAS MUT or platinum sensitive ovarian cancer without BRCA1/2 mutations with CR/PR on prior PARP inhibitor

Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)

CA, CO, CT, FL, GA, IL, KS, KY, LA, MD, MO, NC, PA, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers
ZEN-3694	ZEN003694, BET bromodomain inhibitor ZEN-3694	BET inhibitor	Clinical Trials

II

Platinum resistant or refractory ovarian cancer

A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors

AR, CA, FL, GA, LA, NY, OH, TN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Navicixizumab	OMP-305B83, anti-DLL4/VEGF bispecific monoclonal antibody OMP-305B83	DLL4 and VEGF antagonist	Clinical Trials

II

Platinum resistant ovarian cancer (at most 3 prior therapies for platinum resistant disease)

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Patients With Recurrent Platinum-resistant Ovarian Cancer: Phase II Study

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Evorpacept	CD47/SIRPa-blocking agent ALX148, CD47 antagonist ALX-148, ALX148	Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis	Clinical Trials
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum resistant high grade serous ovarian cancer; at most one prior line of therapy for platinum resistant disease

Phase II Clinical Trial of PLX038 in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
PLX038	pegylated SN-38 conjugate PLX038	Topoisomerase I inhibitor	Clinical Trials

II

Platinum resistant or refractory ovarian cancer

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

DC, NJ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
NY-ESO-1 Peptide vaccine		Immune response against cancer expressing NY-ESO-1	Clinical Trials

II

Advanced solid tumors

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

CA, MA, MI, NJ, NM, NY, OH, TN, TX, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Datopotamab deruxtecan	Dato-DXd, Anti-TROP2/DXd antibody-drug conjugate DS-1062a	ADC: anti-TROP2 + topoisomerase I inhibitor (Dxd)	Clinical Trials

II

Recurrent high grade serous, endometrioid or mucinous ovarian cancer with alterations in RAS, BRAF or NF1

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)

NM, OK

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Avutometinib	CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766	RAF and MEK inhibitor	Clinical Trials
Defactinib	VS-6063, PF-04554878, PF-04554878	FAK inhibitor	Clinical Trials

II

Recurrent ovarian cancer with ARID1A mutations

Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)

OK

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

II

Platinum resistant or refractory ovarian cancer

Phase II Clinical Trial Combining the Hedgehog Inhibitor Vismodegib With the PD-L1 Inhibitor Atezolizumab in Patients With Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Vismodegib	Hedgehog antagonist GDC-0449, Erivedge, GDC-0449	Smoothened antagonist	Approved in Other Cancers

II

Recurrent or persistent ovarian cancer with alterations in BRAF, HRAS, KRAS, NRAS, MEK1/2 or NF1

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

AL, AZ, CA, FL, HI, ID, IL, IA, KY, LA, ME, MD, MA, MI, MN, MO, MT, NV, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SD, TX, VA, WA, WV, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer
Selumetinib	ARRY-142886, AZD6244, Koselugo	MEK1/2 inhibitor	Approved in Other Cancers

II

Advanced solid tumors with alterations in BRAF, HRAS, KRAS, NRAS or RAF, or low grade serous ovarian cancer with progression on prior MEK inhibitor

Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial

AL, CO, FL, ID, IL, IA, KY, ME, MD, MA, MI, MN, MO, MT, NV, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TX, VA, WA, WV, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Binimetinib	MEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, Mektovi	MEK inhibitor	Approved in Other Cancers
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers

II

Advanced solid tumors with an activating AKT mutation, or a loss of function PTEN alteration

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With PTEN/AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

AL, AZ, CA, FL, ID, IL, IA, KY, ME, MD, MA, MI, MN, MT, NV, NJ, NY, NC, ND, OH, OK, OR, PA, SD, TX, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid cancers with a BRAF fusion or a BRAF V600 MUT

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

CA, FL, MD, MA, MN, MO, NE, NJ, NY, OH, RI, TX, WA, WV

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cobicistat	GS 9350	CYP3A inhibitor	Approved in Other Indications
Plixorafenib	8394, BRAF inhibitor PLX8394, FORE8394	BRAF kinase inhibitor	Clinical Trials

II

Recurrent carcinosarcoma

A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced CD30+ nonseminomatous germ cell tumors

Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT)

NC

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ATLCAR.CD30	autologous CD30CAR-CD28-CD3zeta-expressing T lymphocytes	Immune response against cancer expressing CD30	Clinical Trials

II

Advanced solid tumors with a KRAS G12C mutation

A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

AL, CA, FL, ID, IL, IA, KY, ME, MD, MI, MN, MO, MT, NV, NJ, NM, NY, OH, OK, OR, PA, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Panitumumab	Vectibix, ABX-EGF, Clone E7.6.3, ABX-EGF Monoclonal Antibody	EGFR antagonist
Sotorasib	AMG 510, KRAS mutant-targeting AMG 510, Sotorasib	KRAS G12C inhibitor	Approved in Other Cancers

II

Recurrent ovarian cancer

A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

IN, MN, NY, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Sacituzumab tirumotecan	sac-TMT, MK-2870, SKB264	ADC: anti-TROP2 + topoisomerase I inhibitor (KL610023)	Clinical Trials

II

Advanced HER2+ solid tumors with brain metastases

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers
Tucatinib	Irbinitinib, ONT-380	HER2 kinase inhibitor	Approved in Other Cancers

II

Advanced solid tumors with active brain metastases and with alterations in ATM, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, RAD51, RAD51B/C/D, RAD52, or RAD54L

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Dostarlimab	TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

II

Recurrent rare tumors

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab

MD, OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tiragolumab	MTIG7192A, RO7092284	Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cells	Clinical Trials

II

Advanced solid tumors

Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers

IL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Devimistat	alpha-lipoic acid analogue CPI-613, CPI-613	Inhibits metabolic and regulatory processes required for cell growth	Clinical Trials
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Hydroxychloroquine	Plaquenil	Autophagy inhibitor

II

Recurrent ovarian cancer

Combination of the Hypomethylating Agent Decitabine and the Nuclear Export Receptor XPO-1 Inhibitor Selinexor to Reverse Platinum Resistance in Relapsed/Refractory Epithelial Ovarian Cancer

IL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Decitabine	dezocitidine, deoxyazacytidine, 5-aza-dCyd, Dacogen	DNA methylation inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Selinexor	selective inhibitor of nuclear export KPT-330, CRM1 nuclear export inhibitor KPT-330, KPT-330, Xpovio	Selective inhibition of nuclear export (SINE)	Approved in Other Cancers

II

Platinum resistant high grade serous ovarian cancer

Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

GA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atovaquone		Pyrimidine and DNA synthesis inhibitor	Approved in Other Indications

II

Platinum resistant HER2+ ovarian cancer

A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2

AZ, CA, CO, CT, FL, GA, MA, MI, MN, MT, NM, NY, NC, OH, OR, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Disitamab vedotin	anti-HER2 ADC RC48, RC48-ADC	ADC: anti-HER2 + microtubule destabilizer (MMAE)	Clinical Trials

II

Platinum resistant ovarian cancer

A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Recurrent or Persistent Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

CT

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Sacituzumab govitecan	Trodelvy, hrS7-SN38 antibody drug conjugate, anti-TROP-2 Antibody-Drug Conjugate IMMU-132	ADC: anti-TROP2 + topoisomerase I inhibitor (SN38)	Approved in Other Cancers

II

Advanced solid tumors with ERBB2 AMP

A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

AL, CA, ID, IL, IA, KY, ME, MD, MI, MN, MO, MT, NV, NJ, NY, NC, OH, OK, OR, PA, TX, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Neratinib	HKI-272, PD272	EGFR, HER2, HER4 kinase inhibitor	Approved in Other Cancers
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers

II

Advanced HER3+ solid tumors

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

CA, MO, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Patritumab deruxtecan	anti-HER3 antibody-drug conjugate U3 1402	ADC: anti-HER3 + topoisomerase I inhibitor (Dxd)	Clinical Trials

II

Recurrent or persistent mesonephric or mesonephric-like gynecologic cancer; no prior FAK, RAF or MEK inhibitor

Single Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Avutometinib	CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766	RAF and MEK inhibitor	Clinical Trials
Defactinib	VS-6063, PF-04554878, PF-04554878	FAK inhibitor	Clinical Trials

II

Advanced solid tumors

A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
IBI363	anti-PD-1/IL-2 bispecific antibody fusion protein IBI363	Stimulates IL-2R to increase T and NK cell activation and immune response and blocks PD-L1/2 inhibition of T cells	Clinical Trials

II

Platinum resistant or refractory high grade serous ovarian cancer

A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

FL, LA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
CBX-12		ADC: anti-low pH cell surface + topoisomerase I inhibitor (exatecan)	Clinical Trials

II

Platinum resistant CLDN6+ high grade serous or endometrioid ovarian cancer

Catalina-2: a Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women with Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
TORL-1-23		ADC: anti-CLDN6 + microtubule destabilizer (MMAE)	Clinical Trials

II

Platinum resistant high grade serous or endometrioid ovarian cancer with prior bevacizumab

A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
M-CENK	autologous memory cytokine-enriched natural killer cells	Anti-tumor immune response	Clinical Trials
Nogapendekin alfa	N-803, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex N-803, ALT-803	IL-15R agonist	Approved in Other Cancers

Ib/II

Advanced solid tumors (Phase II)

A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors

AZ, CA, FL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Muzastotug	anti-CTLA-4 monoclonal antibody ADG126, anti-CTLA-4 SAFEbody ADG126, ADG126	Blocks CTLA-4 inhibition of T cells	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

Ib/II

Platinum resistant high grade serous or endometrioid ovarian cancer with prior bevacizumab

A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

AL, AZ, AR, CA, CO, FL, GA, IL, IA, LA, MD, MA, MI, MO, NJ, NY, NC, OH, OK, OR, PA, RI, SD, TX, UT, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ACR-368	checkpoint kinase 1 inhibitor LY2606368, LY2606368, Prexasertib	Chk1/2 inhibitor	Clinical Trials
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer

Ib

Recurrent high grade serous or endometrioid ovarian cancer with disease isolated to the abdomen or pelvis - intraperitoneal infusion

A Phase 1b Study of Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cell Therapy in Recurrent Ovarian Cancer

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
CIML NK cell therapy	Cytokine-Induced Memory-like Natural Killer Cells	Anti-tumor immune response	Clinical Trials

Ib

Recurrent ovarian cancer

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

AZ, CA, NJ, NY, OR, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
TRK-950	monoclonal antibody TRK-950	Undisclosed mechanism	Clinical Trials

I/IIa

Advanced solid tumors with prior PD-1/PD-L1 inhibitor therapy (Phase II)

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab

CA, CT, MA, NM, NY, PA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
LNS8801	G protein-coupled estrogen receptor agonist LNS8801	GPER agonist	Clinical Trials

I/IIa

Advanced solid tumors with an ATM alteration (Phase II)

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

AL, AR, CO, FL, IN, NY, OK, PA, TN, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ART0380		ATR kinase inhibitor	Clinical Trials

I/IIa

Platinum resistant or refractory ovarian cancer

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies

CA, PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BI-1808	anti-TNFR2 monoclonal antibody BI-1808	TNFR2 antagonist	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/IIa

Recurrent B7H4+ ovarian cancer

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)

CA, LA, MD, MA, MO, NM, NY, NC, PA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Puxitatug samrotecan	AZD8205	ADC: anti-B7H4 + topoisomerase I inhibitor (AZ14170132)	Clinical Trials
Rilvegostomig	AZD2936, anti-PD-1/anti-TIGIT bispecific antibody AZD2936	Block TIGIT signaling and PD-1 interaction with PD-L1 and PD-L2 to increase NK and T cell activation and immune response	Clinical Trials

I/IIa

Platinum resistant high grade serous ovarian cancer

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors

CA, FL, MI, NY, OH, TN, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BNT327	anti-PD-L1/anti-VEGF-A bispecific antibody PM8002, PM8002	Blocks PD-L1 inhibition of T cells and VEGF antagonist	Clinical Trials
DB-1305		ADC: anti-TROP2 + topoisomerase I inhibitor (P1021)	Clinical Trials

I/II

Recurrent ovarian cancer (Phase II)

Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cediranib	Recentin, Cediranib maleate, AZD2171	VEGFR1-3 kinase inhibitor
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

I/II

Platinum resistant or persistent ovarian cancer

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Defactinib	VS-6063, PF-04554878, PF-04554878	FAK inhibitor	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

I/II

Platinum resistant or refractory ovarian cancer with CA125 levels at least 2 x ULN (Phase II)

A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

AL, MA, MN, NY, OH, OK, TN, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cemiplimab	anti-PD-1 monoclonal antibody REGN2810, REGN2810, Libtayo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Sarilumab	Kevzara	IL-6R antagonist	Approved in Other Indications
Ubamatamab	REGN4018, anti-MUC16/CD3 bispecific antibody REGN4018	Re-directs T cells to attack MUC16 (CA125)+ tumor cells	Clinical Trials

I/II

Advanced solid tumor with high MSI or dMMR who have progressed on prior PD-1/PD-L1 inhibitor therapy - intratumoral injection (Phase II)

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

AZ, AR, CA, FL, IA, KY, MN, NJ, NY, NC, OH, SC, TN, TX, UT, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
RP1	oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus	Induces immune response and tumor cell lysis	Clinical Trials

I/II

Advanced solid tumors with RAS mutations (Phase II)

Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers

VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Neratinib	HKI-272, PD272	EGFR, HER2, HER4 kinase inhibitor	Approved in Other Cancers
Valproic acid	Depacon, Depakene, Stavzor, Valproate	HDAC and NOS inhibitor	Approved in Other Indications

I/II

Recurrent clear cell ovarian cancer with ARID1A mutations and with prior bevacizumab (Phase II)

A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

GA, IL, MA, MI, NJ, NY, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Tulmimetostat	CPI-0209, EZH2 inhibitor CPI-0209	EZH2 histone methyltransferase inhibitor	Clinical Trials

I/II

Advanced solid tumors (Phase II)

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression

CA, CO, FL, MI, NY, OK, PA, TN, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BT5528	BT5528 - an EphA2-targeting Bicycle Toxin Conjugate, BT5528-100	ADC: anti-EphA2 + microtubule destabilizer (MMAE)	Clinical Trials
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Advanced PRAME+ solid tumors - optional subcutaneous injection (Phase II)

Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers

CA, CO, DC, FL, IL, IA, MA, NJ, NY, OK, PA, SC, TN, TX, UT, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Brenetafusp	IMC-F106C, a T cell redirecting bi-specific biologic, IMC-F106C	Re-directs T cells to attack PRAME+ tumor cells	Clinical Trials
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Platinum resistant ovarian cancer

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

CA, FL, GA, IL, MD, NY, OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Farletuzumab ecteribulin	MORAb-202	ADC: anti-FRalpha + microtubule destabilizer (eribulin)	Clinical Trials

I/II

Advanced solid tumors with ALK, ROS1 or NTRK1-3 alterations (Phase II)

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, NC, OH, PA, TN, TX, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Repotrectinib	TPX-0005, ALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005	ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitor	Approved in Other Cancers

I/II

Advanced solid tumors with MET amplifications or MET gene fusions (Phase II)

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

CA, DE, FL, MD, MA, MN, MO, NC, OH, PA, SC, TN, TX, WV, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Vebreltinib	CBT-101, APL-101, Bozitinib	c-Met kinase inhibitor	Clinical Trials

I/II

Advanced solid tumors with a NRG1 gene fusion (Phase II)

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

CA, DC, FL, GA, IL, MA, MI, MT, NY, PA, TX, UT, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Zenocutuzumab	MCLA-128, anti-HER2/Anti-HER3 bispecific monoclonal antibody MCLA-128	Docks on HER2 and blocks NRG-1 mediated growth of tumor cells by binding to HER3	Approved in Other Cancers

I/II

Advanced solid tumors with alterations in ATM, BRCA1/2, CDK12, CHEK2, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, SETD2 (Phase II)

Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)

IL, NY, RI, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Camonsertib	RP-3500	ATR kinase inhibitor	Clinical Trials
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers

I/II

Advanced solid tumors (Phase II)

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies

CO, FL, NY, OH, PA, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BT8009	BT8009 - a Nectin-4-targeting Bicycle Toxin Conjugate, BT8009-100	ADC: anti-Nectin-4 + microtubule destabilizer (MMAE)	Clinical Trials

I/II

Recurrent ovarian cancer with a TP53 Y220C mutation and without a KRAS mutation (Phase II)

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

CA, CO, CT, FL, IL, MA, MI, NY, NC, OH, OK, OR, PA, SC, TN, TX, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Rezatapopt	PC14586	p53 Y220C activator	Clinical Trials

I/II

Recurrent ovarian cancer

Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)

CA, FL, IL, MA, MI, NY, OH, PA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cemiplimab	anti-PD-1 monoclonal antibody REGN2810, REGN2810, Libtayo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
REGN5668		Stimulates CD28 to increase T cell activation and immune response against MUC16 (CA125) expressing tumor cells	Clinical Trials
Ubamatamab	REGN4018, anti-MUC16/CD3 bispecific antibody REGN4018	Re-directs T cells to attack MUC16 (CA125)+ tumor cells	Clinical Trials

I/II

Recurrent ovarian cancer with high levels of γ9δ2 T cells

A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer

CT, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ICT01		Activates gamma/delta T cells to stimulate immune response	Clinical Trials

I/II

Advanced solid tumors with alterations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, PPP2R2A, RAD51B/C/D, or RAD54L or HRD+ or high LOH with progression on or within 6 months after prior PARP inhibitor treatment (Phase II)

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Berzosertib	ATR kinase inhibitor VX-970, VE-822, M6620, VX-970	ATR kinase inhibitor	Clinical Trials
Sacituzumab govitecan	Trodelvy, hrS7-SN38 antibody drug conjugate, anti-TROP-2 Antibody-Drug Conjugate IMMU-132	ADC: anti-TROP2 + topoisomerase I inhibitor (SN38)	Approved in Other Cancers

I/II

Advanced solid tumors with inactivating NF2 mutations/alterations or YAP/TAZ gene rearrangements (Phase II)

Phase 1, Multi-Center, Open-Label Study of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (Mutant NF2 or mNF2)

IL, MA, NY, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
VT3989		TEAD inhibitor	Clinical Trials

I/II

Advanced solid tumors with a KRAS G12C mutation (Phase II)

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

AL, CA, CT, FL, IN, LA, MA, NH, NY, NC, PA, TN, TX, UT, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olomorasib	LY3537982	KRAS G12C inhibitor	Clinical Trials

I/II

Platinum resistant or refractory high grade serous or endometrioid ovarian cancer

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

FL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tivozanib	AV-951	VEGFR kinase inhibitor	Approved in Other Cancers

I/II

Platinum resistant ovarian cancer; at most 2 prior therapies for Pt-R disease

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

AZ, AR, CA, CT, FL, KS, MI, NJ, PA, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
NP-G2-044		Fascin inhibitor	Clinical Trials
PD-1i		Blocks PD-L1/2 inhibition of T cells

I/II

Platinum resistant ovarian cancer (Phase II)

IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

CA, MA, NY, OH, OK, PA, TN, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Docetaxel	Taxotere	Microtubule stabilizer/mitotic inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pemetrexed	Pemetrexed disodium, Alimta	DHFR and Thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer
TransCon IL-2 β/γ		IL-2R/IL-15R beta and gamma agonist	Clinical Trials

I/II

Advanced solid tumors with ROS1 rearrangement (Phase II)

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)

CA, CO, DC, FL, MA, MI, MO, NY, NC, OH, PA, TN, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
NVL-520		ROS1 kinase inhibitor	Clinical Trials

I/II

Platinum resistant or refractory ovarian cancer with CCNE1 amplification

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors

AR, CA, FL, IL, MD, MA, MI, NY, NC, OK, PA, TN, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BLU-222		CDK2 inhibitor	Clinical Trials
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer

I/II

Recurrent CLDN6+ ovarian cancer

First-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid Tumors

IN, MD, NY, NC, PA, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BNT142	BNT142 RiboMab (mRNA-encoded antibody)	Re-directs T cells to attack CLDN6+ tumor cells	Clinical Trials

I/II

Recurrent ovarian cancer (Phase II)

Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors

AZ, CA, FL, KS, MD, MA, MI, MN, OK, RI, TN, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Rinatabart sesutecan	PRO1184	ADC: anti-FRalpha + topoisomerase I inhibitor (exatecan)	Clinical Trials

I/II

Advanced solid tumors with high TMB or high MSI (Phase II)

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

FL, MD, MA, NY, OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Invikafusp alfa	anti-TCR Vb6/Vb10/IL-2 antibody fusion protein STAR0602, STAR0602	Activates alpha/beta T cells to stimulate immune response	Clinical Trials

I/II

Platinum resistant or refractory ovarian cancer

Combination Therapy With Liposomal Doxorubicin and Withaferin A (Ashwagandha, ASWD) in Recurrent Ovarian Cancer

KY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ashwagandha	ashwagandha root powder extract	Downregulates NF-kappaB	Clinical Trials
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer

I/II

Advanced solid tumors with a RAS G12V mutation

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Anti-KRAS G12V mTCR PBL		Immune response against cancer expressing RAS G12V	Clinical Trials
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers

I/II

Platinum resistant or refractory ovarian cancer with CCNE1 AMP

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer

GA, MA, NC, OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
INX-315		CDK2 inhibitor	Clinical Trials

I/II

Advanced solid tumors (inc ovarian expansion)

A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
SON-1010	SON1010, recombinant albumin-binding IL-12 SON-1010, SON 1010	IL-12R agonist	Clinical Trials

I/II

Platinum resistant ovarian cancer

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

CA, CO, KY, MA, OH, OR, RI, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
AZD5335	anti-FRa antibody-drug conjugate AZD5335	ADC: anti-FRalpha + topoisomerase I inhibitor (AZ14170132)	Clinical Trials
Saruparib	AZD5305	PARP1 inhibitor	Clinical Trials

I/II

Platinum resistant or refractory ovarian cancer with CCNE1 amplification

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

CT, FL, OH, OK, PA, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
AVZO-021	ARTS-021	CDK2 inhibitor	Clinical Trials
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer

I/II

Advanced solid tumors (Phase II)

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors

AZ, CA, FL, GA, KY, MN, NV, NY, OH, SC, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
DB-1311	BNT324	ADC: anti-B7H3 + topoisomerase I inhibitor (P1021)	Clinical Trials

I/II

Recurrent ovarian cancer; all lesions must be less than 5 cm

MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)

AZ, FL, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
FRalpha DC vaccine	Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, FRalphaDCs	Immune response against cancer expressing folate receptor	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Platinum resistant high grade serous or mesonephric-like TROP2+ ovarian cancer - intraperitoneal infusion

Phase I/II Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
TROP2-CAR-NK		Immune response against cancer expressing TROP2 enhanced by IL-15R stimulation	Clinical Trials

I/II

Recurrent clear cell ovarian cancer without a PPP2R1A mutation

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Dostarlimab	TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
LB-100	protein phosphatase 2A inhibitor LB-100	PP2A inhibitor	Clinical Trials

I/II

Platinum resistant or refractory ovarian cancer

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

FL, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
VIO-01		DNA Repair decoy	Clinical Trials

I/II

Platinum resistant ovarian cancer

A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

OH, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
TUB-040		ADC: anti-NaPi2b + topoisomerase I inhibitor (exatecan)	Clinical Trials